Stem cell therapy vs exosome therapy
The two are often marketed as alternatives to the same problem. They are better understood as a cell and its secretions: MSC therapy delivers living cells, exosome therapy delivers part of what those cells release. The evidence base behind them is not equivalent.
Side by side
| MSC therapy | Exosome therapy | |
|---|---|---|
| Material | Living mesenchymal stromal cells | Nanoscale extracellular vesicles |
| Proposed mechanism | Paracrine signalling, immunomodulation, homing to injury | Delivery of proteins, lipids and RNA cargo |
| Controlled human trials | Numerous, across many indications — search PubMed | Few — search PubMed |
| Typical routes | IV, intrathecal, intra-articular, image-guided local | IV, local, topical (dermatology) |
| Main safety questions | Infusion reactions, product sterility, long-term follow-up | Product characterisation and sterility; smaller safety dataset |
| Relative cost | Higher (cell expansion, release testing) | Lower |
| Regulatory status | Unlicensed for these indications in US/EU/UK | Unlicensed; FDA safety notification in force |
Should I choose stem cell therapy or exosome therapy?
Cell therapy transfers living mesenchymal stem cells; exosome therapy transfers their signalling vesicles. Cell therapy has more human evidence and higher cost; exosome therapy is cheaper, simpler to handle and much less studied in controlled human trials. The reasonable choice depends on the indication, the evidence for it, and what your clinician can justify in writing — not on price.
Key facts
- Cells
- More human evidence, higher cost, hospital administration
- Exosomes
- Lower cost, thinner evidence, simpler handling
- Combined
- Offered by some clinics; evidence for the combination is minimal
What we know
- Both products can be manufactured and tested to documented criteria.
What remains uncertain
- No controlled trial has established that either is superior for the indications commonly marketed.
| MSC therapy | Exosome therapy | |
|---|---|---|
| What is given | Living cells | Cell-derived vesicles |
| Human evidence | Early to randomised, indication-dependent | Mostly early-phase |
| Typical quote | €6,000 – €25,000 | €3,500 – €8,000 |
| Release testing | Identity, viability, sterility, endotoxin, mycoplasma | Particle count, sterility, endotoxin |
Medically reviewed questions
This summary is general medical information, not medical advice, and not a promise of benefit. Figures are quoted ranges, confirmed in writing after a medical review.
Medically reviewed by: Prof. Dr. Erdal Karaöz · Last updated: · Editorial and evidence policy
When each is considered
MSC therapy is considered when
The indication has at least early controlled human data, the patient is medically suitable for the route required, and standard care has been optimised first.
Exosomes are considered when
A cell-free option is preferred for handling or clinical reasons, or in indications such as dermatology and hair where most of the human exosome literature sits.
Both together
Only where there is a clinical rationale documented in your protocol. Combined programmes.
Neither
Where the evidence for your indication is preclinical only, or where standard treatment has not been tried. Declining is a legitimate outcome of the records review.
How to compare quotes fairly
- Compare cell dose and number of applications, not headline price.
- Ask whether exosome doses are quantified by particle count, not by "vials".
- Check whether hospital, imaging, medication and follow-up are included in both quotes.
- Ask for the release documentation for whichever product is being proposed.
Frequently asked questions
Which one works better?
There is no head-to-head randomised trial that answers this for the indications patients ask about, so any claim that one is superior is not evidence-based. MSC therapy simply has more controlled human data behind it.
Are exosomes 'stem cells without the risk'?
No. That framing is marketing. Exosomes avoid some cell-specific risks, but product characterisation and sterility remain critical and the human dataset is smaller.
Read next
Have your records reviewed first
Whether any of this applies to you can only be decided after a physician reviews your medical records. The review is free and there is no obligation to travel.
Request a free medical review